Fulcrum Therapeutics and Slate Medicines Merge in $245 Million Migraine Reverse Merger
Fulcrum Therapeutics and privately held Slate Medicines entered a definitive all-stock merger centered on Slate’s migraine pipeline and a concurrent $245 million private placement led by Frazier Life Sciences. The combined company is expected…
